Mass Cytometry: A Highly Multiplexed Single-Cell Technology for Advancing Drug Development

Abstract

Advanced single-cell analysis technologies (e.g., mass cytometry) that help in multiplexing cellular measurements in limited-volume primary samples are critical in bridging discovery efforts to successful drug approval. Mass cytometry is the state-of-the-art technology in multiparametric single-cell analysis. Mass cytometers (also known as cytometry by time-of-flight or CyTOF) combine the cellular analysis principles of traditional fluorescence-based flow cytometry with the selectivity and quantitative power of inductively coupled plasma-mass spectrometry. Standard flow cytometry is limited in the number of parameters that can be measured owing to the overlap in signal when detecting fluorescently labeled antibodies. Mass cytometry uses antibodies tagged to stable isotopes of rare earth metals, which requires minimal signal compensation between the different metal tags. This unique feature enables researchers to seamlessly multiplex up to 40 independent measurements on single cells. In this overview we first present an overview of mass cytometry and compare it with traditional flow cytometry. We then discuss the emerging and potential applications of CyTOF technology in the pharmaceutical industry, including quantitative and qualitative deep profiling of immune cells and their applications in assessing drug immunogenicity, extensive mapping of signaling networks in single cells, cell surface receptor quantification and multiplexed internalization kinetics, multiplexing sample analysis by barcoding, and establishing cell ontologies on the basis of phenotype and/or function. We end with a discussion of the anticipated impact of this technology on drug development lifecycle with special emphasis on the utility of mass cytometry in deciphering a drug's pharmacokinetics and pharmacodynamics relationship.

Lanthanide‐Coordinated Semiconducting Polymer Dots Used for Flow Cytometry and Mass Cytometry

“…Highly multiplexed detection of biomarkers in individual cells will impact cell research, [1] drug discovery, [2] disease diagnosis, and treatment. [3] Clinical samples are scarce so high-throughput assays are critical for efficiently extracting as much information as possible from limited samples.…”

Flow-SNE: A New Approach for Flow Cytometry Clustering and Visualization

“…But the clustering time is very short and for MBM dataset, it takes around 20 seconds. Such high performance makes our algorithm suitable for future cytometry data [28] that large number of cells and markers are expected. Similar to the DLBCL and GvHD datasets, the expression of different cellular markers of MBM are presented in Figure 11.…”

Mass spectrometry-based proteomic exploration of the human immune system: focus on the inflammasome, global protein secretion, and T cells

“…The main advantages of these assays are that they are not dependent on the available antibodies and that they can be fully automated. multiplexing of up to 40 independent measurements on a single cell is possible [105,106].…”